Proteins and Peptides

28 July 2015

MonoSol Rx Announces Initiation of Phase 2a Trial for Oral Insulin Film

27 July 2015

Baxalta’s OBIZUR for Acquired Hemophilia A Receives Positive Opinion from European Committee for Medicinal Products for Human Use (CHMP)

25 July 2015

FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

23 July 2015

Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma

20 July 2015

CollPlant Reports Positive Interim Trial Results for Vergenix™STR, for the Treatment of Tendinopathy

17 July 2015

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States

16 July 2015

Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A

16 July 2015

Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs into Clinical Development

16 July 2015

Sobi exercises opt-in right for Alprolix®

15 July 2015

OptiNose Announces Positive Early Phase Clinical Trial with OPN-300, an Investigational Product in Development for Treatment of Autism Spectrum Disorders

15 July 2015

Cerenis Therapeutics Announces the Results of the LOCATION Study

14 July 2015

Scioderm to Submit Rolling NDA to U.S. FDA for ZorblisaTM

14 July 2015

Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation

14 July 2015

Allegro Ophthalmics Announces Positive Topline Results from Phase 2 Trial Evaluating Luminate® in Patients with Vitreomacular Traction or Vitreomacular Adhesion

13 July 2015

Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes

10 July 2015

OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults

10 July 2015

Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo

7 July 2015

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury

6 July 2015

Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial

30 June 2015

CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform

30 June 2015

Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study

30 June 2015

Susavion Biosciences Discovers A Novel Type of Checkpoint Inhibitor

29 June 2015

CSL Behring Receives Positive CHMP Opinion for Respreeza® (human alpha-1 proteinase inhibitor) as Maintenance Treatment for Patients with Severe Alpha-1 Antitrypsin Deficiency in Europe

27 June 2015

Aratana Therapeutics Announces Positive Pivotal Results for AT-002

26 June 2015

Levemir® receives positive CHMP opinion for extended use in children as young as one year old

26 June 2015

Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union

26 June 2015

Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy

25 June 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

24 June 2015

Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation Coagulation Factor VIIa in Patients With Hemophilia A or B and Preclinical Results From Its Factor IX and Factor Xa Programs

24 June 2015

In a Phase 3 Trial, Novoeight®(Antihemophilic Factor [Recombinant]) Provided Long-term Efficacy and Safety in the Prophylaxis and Treatment of Bleeds in People with Hemophilia A

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

CD73 Inhibitor Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Ustekinumab (Stelara) Biosimilars Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins